Filing Flows › Comparisons › NVS vs GSK
Novartis AG vs GSK: NVS and GSK compared
Novartis AG is the larger company: $14.5B of revenue in its latest quarter (Q3 2026) against $8.5B for GSK (Q3 2026). GSK is more profitable, with an operating margin of 30.3% against 12.7%.
Where the money goes: NVS and GSK
Novartis AG (NVS) · Q3 2026
Novartis AG, Q3 2026: revenue $14.5B (+4% year over year), operating margin 12.7%, net earnings $1.2B, operating cash flow $5.5B. The chart follows the revenue to costs, profit and cash.
GSK (GSK) · Q3 2026
GSK, Q3 2026: revenue $8.5B, operating margin 30.3%, net earnings $2.0B. The chart follows the revenue to costs, profit and cash.
| Novartis AG (NVS) | GSK (GSK) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $14.5B | $8.5B |
| Revenue growth, Y/Y | +4% | — |
| Gross margin | — | 73.6% |
| Operating margin | 12.7% | 30.3% |
| Net earnings | $1.2B | $2.0B |
| Net margin | 8.2% | 23.6% |
| Operating cash flow | $5.5B | — |
Where the revenue comes from
GSK
- Specialty Medicines: $3.9B (45%)
- Dolutegravir products: $1.4B (17%)
- Dovato: $754M (9%)
- Long Acting Injectables: $621M (7%)
Questions
Which is bigger, Novartis AG or GSK?
Novartis AG is the larger company: $14.5B of revenue in its latest quarter (Q3 2026) against $8.5B for GSK (Q3 2026).
Is Novartis AG or GSK growing faster?
GSK is more profitable, with an operating margin of 30.3% against 12.7%.
More: Novartis AG earnings · how Novartis AG makes money · GSK earnings · how GSK makes money
From the companies' latest 10-Q, 10-K or earnings release (6-K filed Oct 27, 2026; 6-K filed Oct 28, 2026). Fiscal quarters can end on different dates. Not investment advice.